{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T23:09:11Z","timestamp":1793056151438,"version":"4.5.0"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,10,30]],"date-time":"2023-10-30T00:00:00Z","timestamp":1698624000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,10,30]],"date-time":"2023-10-30T00:00:00Z","timestamp":1698624000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2024,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Myelomonocytic and monocytic acute myeloid leukemia (AML) subtypes are intrinsically resistant to venetoclax-based regimens. Identifying targetable vulnerabilities would limit resistance and relapse. We previously documented the synergism of venetoclax and cardiac glycoside (CG) combination in AML. Despite preclinical evidence, the repurposing of cardiac glycosides (CGs) in cancer therapy remained unsuccessful due to a lack of predictive biomarkers. We report that the ex vivo response of AML patient blasts and the in vitro sensitivity of established cell lines to the hemi-synthetic CG UNBS1450 correlates with the ATPase Na\n                    <jats:sup>+<\/jats:sup>\n                    \/K\n                    <jats:sup>+<\/jats:sup>\n                    transporting subunit alpha 1 (ATP1A1)\/BCL2 like 1 (BCL2L1) expression ratio. Publicly available AML datasets identify myelomonocytic\/monocytic differentiation as the most robust prognostic feature, along with core-binding factor subunit beta (\n                    <jats:italic>CBFB<\/jats:italic>\n                    ), lysine methyltransferase 2A (\n                    <jats:italic>KMT2A<\/jats:italic>\n                    ) rearrangements, and missense Fms-related receptor tyrosine kinase 3 (\n                    <jats:italic>FLT3<\/jats:italic>\n                    ) mutations. Mechanistically, BCL2L1 protects from cell death commitment induced by the CG-mediated stepwise triggering of ionic perturbation, protein synthesis inhibition, and MCL1 downregulation. In vivo, CGs showed an overall tolerable profile while impacting tumor growth with an effect ranging from tumor growth inhibition to regression. These findings suggest a predictive marker for CG repurposing in specific AML subtypes.\n                  <\/jats:p>","DOI":"10.1038\/s41375-023-02076-8","type":"journal-article","created":{"date-parts":[[2023,10,30]],"date-time":"2023-10-30T10:01:43Z","timestamp":1698660103000},"page":"67-81","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["ATP1A1\/BCL2L1 predicts the response of myelomonocytic and monocytic acute myeloid leukemia to cardiac glycosides"],"prefix":"10.1038","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9308-8176","authenticated-orcid":false,"given":"Claudia","family":"Cerella","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0964-8308","authenticated-orcid":false,"given":"Sruthi Reddy","family":"Gajulapalli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Lorant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6083-6614","authenticated-orcid":false,"given":"Deborah","family":"Gerard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Muller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yejin","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyung Rok","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Byung Woo","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christo","family":"Christov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"R\u00e9cher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6704-2032","authenticated-orcid":false,"given":"Jean-Emmanuel","family":"Sarry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Dicato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0115-4725","authenticated-orcid":false,"given":"Marc","family":"Diederich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,10,30]]},"reference":[{"key":"2076_CR1","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1158\/2159-8290.CD-19-0710","volume":"10","author":"S Pei","year":"2020","unstructured":"Pei S, Pollyea DA, Gustafson A, Stevens BM, Minhajuddin M, Fu R, et al. Monocytic subclones confer resistance to venetoclax-based therapy in patients with acute myeloid leukemia. Cancer Discov. 2020;10:536\u201351.","journal-title":"Cancer Discov"},{"key":"2076_CR2","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1038\/s43018-020-0103-x","volume":"1","author":"H Zhang","year":"2020","unstructured":"Zhang H, Nakauchi Y, Kohnke T, Stafford M, Bottomly D, Thomas R, et al. Integrated analysis of patient samples identifies biomarkers for venetoclax efficacy and combination strategies in acute myeloid leukemia. Nat Cancer. 2020;1:826\u201339.","journal-title":"Nat Cancer"},{"key":"2076_CR3","doi-asserted-by":"crossref","first-page":"708","DOI":"10.3324\/haematol.2018.214882","volume":"105","author":"H Kuusanmaki","year":"2020","unstructured":"Kuusanmaki H, Leppa AM, Polonen P, Kontro M, Dufva O, Deb D, et al. Phenotype-based drug screening reveals association between venetoclax response and differentiation stage in acute myeloid leukemia. Haematologica. 2020;105:708\u201320.","journal-title":"Haematologica"},{"key":"2076_CR4","volume":"5","author":"BS White","year":"2021","unstructured":"White BS, Khan SA, Mason MJ, Ammad-Ud-Din M, Potdar S, Malani D, et al. Bayesian multi-source regression and monocyte-associated gene expression predict BCL-2 inhibitor resistance in acute myeloid leukemia. NPJ Precis Oncol. 2021;5:71.","journal-title":"NPJ Precis Oncol"},{"key":"2076_CR5","doi-asserted-by":"crossref","first-page":"3062","DOI":"10.1182\/bloodadvances.2021006307","volume":"6","author":"SE Kurtz","year":"2022","unstructured":"Kurtz SE, Eide CA, Kaempf A, Long N, Bottomly D, Nikolova O, et al. Associating drug sensitivity with differentiation status identifies effective combinations for acute myeloid leukemia. Blood Adv. 2022;6:3062\u20137.","journal-title":"Blood Adv"},{"key":"2076_CR6","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1158\/2643-3230.BCD-21-0012","volume":"2","author":"KA Romine","year":"2021","unstructured":"Romine KA, Nechiporuk T, Bottomly D, Jeng S, McWeeney SK, Kaempf A, et al. Monocytic differentiation and AHR signaling as primary nodes of BET inhibitor response in acute myeloid leukemia. Blood Cancer Discov. 2021;2:518\u201331.","journal-title":"Blood Cancer Discov"},{"key":"2076_CR7","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1002\/cyto.b.21280","volume":"92","author":"C Lambert","year":"2017","unstructured":"Lambert C, Preijers F, Yanikkaya Demirel G, Sack U. Monocytes and macrophages in flow: an ESCCA initiative on advanced analyses of monocyte lineage using flow cytometry. Cytometry B Clin Cytom. 2017;92:180\u20138.","journal-title":"Cytometry B Clin Cytom"},{"key":"2076_CR8","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1182\/bloodadvances.2020003734","volume":"5","author":"M Stahl","year":"2021","unstructured":"Stahl M, Menghrajani K, Derkach A, Chan A, Xiao W, Glass J, et al. Clinical and molecular predictors of response and survival following venetoclax therapy in relapsed\/refractory AML. Blood Adv. 2021;5:1552\u201364.","journal-title":"Blood Adv"},{"key":"2076_CR9","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1158\/2159-8290.CD-22-0939","volume":"13","author":"A Waclawiczek","year":"2023","unstructured":"Waclawiczek A, Leppa AM, Renders S, Stumpf K, Reyneri C, Betz B, et al. Combinatorial BCL2 family expression in acute myeloid leukemia stem cells predicts clinical response to azacitidine\/venetoclax. Cancer Discov. 2023;13:1408\u201327.","journal-title":"Cancer Discov"},{"key":"2076_CR10","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1158\/2159-8290.CD-22-1297","volume":"13","author":"S Pei","year":"2023","unstructured":"Pei S, Shelton IT, Gillen AE, Stevens BM, Gasparetto M, Wang Y, et al. A novel type of monocytic leukemia stem cell revealed by the clinical use of venetoclax-based therapy. Cancer Discov. 2023;13:2032\u201349.","journal-title":"Cancer Discov"},{"key":"2076_CR11","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/j.clml.2021.07.012","volume":"21","author":"A Inguva","year":"2021","unstructured":"Inguva A, Pollyea DA. SOHO state of the art updates and next questions: the past, present and future of venetoclax-based therapies in AML. Clin Lymphoma Myeloma Leuk. 2021;21:805\u201311.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"2076_CR12","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1038\/s43018-020-00126-z","volume":"1","author":"BM Stevens","year":"2020","unstructured":"Stevens BM, Jones CL, Pollyea DA, Culp-Hill R, D\u2019Alessandro A, Winters A, et al. Fatty acid metabolism underlies venetoclax resistance in acute myeloid leukemia stem cells. Nat Cancer. 2020;1:1176\u201387.","journal-title":"Nat Cancer"},{"key":"2076_CR13","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1016\/j.ccell.2020.10.010","volume":"38","author":"S Bhatt","year":"2020","unstructured":"Bhatt S, Pioso MS, Olesinski EA, Yilma B, Ryan JA, Mashaka T, et al. Reduced mitochondrial apoptotic priming drives resistance to BH3 mimetics in acute myeloid leukemia. Cancer Cell. 2020;38:872\u201390 e876.","journal-title":"Cancer Cell"},{"key":"2076_CR14","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1182\/blood.2021011094","volume":"141","author":"H Kuusanmaki","year":"2023","unstructured":"Kuusanmaki H, Dufva O, Vaha-Koskela M, Leppa AM, Huuhtanen J, Vanttinen I, et al. Erythroid\/megakaryocytic differentiation confers BCL-XL dependency and venetoclax resistance in acute myeloid leukemia. Blood. 2023;141:1610\u201325.","journal-title":"Blood"},{"key":"2076_CR15","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.bcp.2010.08.025","volume":"81","author":"T Juncker","year":"2011","unstructured":"Juncker T, Cerella C, Teiten MH, Morceau F, Schumacher M, Ghelfi J, et al. UNBS1450, a steroid cardiac glycoside inducing apoptotic cell death in human leukemia cells. Biochem Pharmacol. 2011;81:13\u201323.","journal-title":"Biochem Pharmacol"},{"key":"2076_CR16","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2015.134","volume":"6","author":"C Cerella","year":"2015","unstructured":"Cerella C, Muller F, Gaigneaux A, Radogna F, Viry E, Chateauvieux S, et al. Early downregulation of Mcl-1 regulates apoptosis triggered by cardiac glycoside UNBS1450. Cell Death Dis. 2015;6:e1782.","journal-title":"Cell Death Dis"},{"key":"2076_CR17","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1038\/leu.2016.341","volume":"31","author":"C Cerella","year":"2017","unstructured":"Cerella C, Gaigneaux A, Mazumder A, Lee JY, Saland E, Radogna F, et al. Bcl-2 protein family expression pattern determines synergistic pro-apoptotic effects of BH3 mimetics with hemisynthetic cardiac glycoside UNBS1450 in acute myeloid leukemia. Leukemia. 2017;31:755\u20139.","journal-title":"Leukemia"},{"key":"2076_CR18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.bcp.2016.08.017","volume":"125","author":"M Diederich","year":"2017","unstructured":"Diederich M, Muller F, Cerella C. Cardiac glycosides: From molecular targets to immunogenic cell death. Biochem Pharmacol. 2017;125:1\u201311.","journal-title":"Biochem Pharmacol"},{"key":"2076_CR19","doi-asserted-by":"crossref","first-page":"104963","DOI":"10.1016\/j.isci.2022.104963","volume":"25","author":"J Zhang","year":"2022","unstructured":"Zhang J, Chang J, Beg MA, Huang W, Zhao Y, Dai W, et al. Na\/K-ATPase suppresses LPS-induced pro-inflammatory signaling through Lyn. iScience. 2022;25:104963.","journal-title":"iScience"},{"key":"2076_CR20","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1038\/s41418-018-0245-x","volume":"26","author":"M Orsini","year":"2019","unstructured":"Orsini M, Chateauvieux S, Rhim J, Gaigneaux A, Cheillan D, Christov C, et al. Sphingolipid-mediated inflammatory signaling leading to autophagy inhibition converts erythropoiesis to myelopoiesis in human hematopoietic stem\/progenitor cells. Cell Death Differ. 2019;26:1796\u2013812.","journal-title":"Cell Death Differ"},{"key":"2076_CR21","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.canlet.2018.07.041","volume":"438","author":"A Mazumder","year":"2018","unstructured":"Mazumder A, Lee JY, Talhi O, Cerella C, Chateauvieux S, Gaigneaux A, et al. Hydroxycoumarin OT-55 kills CML cells alone or in synergy with imatinib or Synribo: involvement of ER stress and DAMP release. Cancer Lett. 2018;438:197\u2013218.","journal-title":"Cancer Lett"},{"key":"2076_CR22","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1016\/j.cell.2019.01.031","volume":"176","author":"P van Galen","year":"2019","unstructured":"van Galen P, Hovestadt V, Wadsworth Ii MH, Hughes TK, Griffin GK, Battaglia S, et al. Single-cell RNA-Seq reveals AML hierarchies relevant to disease progression and immunity. Cell. 2019;176:1265\u201381 e1224.","journal-title":"Cell"},{"key":"2076_CR23","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1016\/j.ccell.2022.07.002","volume":"40","author":"D Bottomly","year":"2022","unstructured":"Bottomly D, Long N, Schultz AR, Kurtz SE, Tognon CE, Johnson K, et al. Integrative analysis of drug response and clinical outcome in acute myeloid leukemia. Cancer Cell. 2022;40:850\u201364 e859.","journal-title":"Cancer Cell"},{"key":"2076_CR24","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1200\/JCO.2012.44.3184","volume":"31","author":"Z Li","year":"2013","unstructured":"Li Z, Herold T, He C, Valk PJ, Chen P, Jurinovic V, et al. Identification of a 24-gene prognostic signature that improves the European LeukemiaNet risk classification of acute myeloid leukemia: an international collaborative study. J Clin Oncol. 2013;31:1172\u201381.","journal-title":"J Clin Oncol"},{"key":"2076_CR25","doi-asserted-by":"crossref","first-page":"4193","DOI":"10.1182\/blood-2008-02-134411","volume":"112","author":"KH Metzeler","year":"2008","unstructured":"Metzeler KH, Hummel M, Bloomfield CD, Spiekermann K, Braess J, Sauerland MC, et al. An 86-probe-set gene-expression signature predicts survival in cytogenetically normal acute myeloid leukemia. Blood. 2008;112:4193\u2013201.","journal-title":"Blood"},{"key":"2076_CR26","doi-asserted-by":"crossref","first-page":"5586","DOI":"10.4049\/jimmunol.1301319","volume":"192","author":"A Rodriguez-Pla","year":"2014","unstructured":"Rodriguez-Pla A, Patel P, Maecker HT, Rossello-Urgell J, Baldwin N, Bennett L, et al. IFN priming is necessary but not sufficient to turn on a migratory dendritic cell program in lupus monocytes. J Immunol. 2014;192:5586\u201398.","journal-title":"J Immunol"},{"key":"2076_CR27","first-page":"1671","volume":"128","author":"TC Ho","year":"2016","unstructured":"Ho TC, LaMere M, Stevens BM, Ashton JM, Myers JR, O\u2019Dwyer KM, et al. Evolution of acute myelogenous leukemia stem cell properties after treatment and progression. Blood. 2016;128:1671\u20138.","journal-title":"Blood"},{"key":"2076_CR28","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1038\/nature13038","volume":"506","author":"LI Shlush","year":"2014","unstructured":"Shlush LI, Zandi S, Mitchell A, Chen WC, Brandwein JM, Gupta V, et al. Identification of pre-leukaemic haematopoietic stem cells in acute leukaemia. Nature. 2014;506:328\u201333.","journal-title":"Nature"},{"key":"2076_CR29","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1038\/nature11003","volume":"483","author":"J Barretina","year":"2012","unstructured":"Barretina J, Caponigro G, Stransky N, Venkatesan K, Margolin AA, Kim S, et al. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature. 2012;483:603\u20137.","journal-title":"Nature"},{"key":"2076_CR30","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1056\/NEJMoa1301689","volume":"368","author":"TJ Ley","year":"2013","unstructured":"Cancer Genome Atlas Research N, Ley TJ, Miller C, Ding L, Raphael BJ, Mungall AJ, et al. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med. 2013;368:2059\u201374.","journal-title":"N Engl J Med"},{"key":"2076_CR31","doi-asserted-by":"crossref","first-page":"10958","DOI":"10.1073\/pnas.1222308110","volume":"110","author":"M Laursen","year":"2013","unstructured":"Laursen M, Yatime L, Nissen P, Fedosova NU. Crystal structure of the high-affinity Na+K+-ATPase-ouabain complex with Mg2+ bound in the cation binding site. Proc Natl Acad Sci USA. 2013;110:10958\u201363.","journal-title":"Proc Natl Acad Sci USA"},{"key":"2076_CR32","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1073\/pnas.1422997112","volume":"112","author":"M Laursen","year":"2015","unstructured":"Laursen M, Gregersen JL, Yatime L, Nissen P, Fedosova NU. Structures and characterization of digoxin- and bufalin-bound Na+,K+-ATPase compared with the ouabain-bound complex. Proc Natl Acad Sci USA. 2015;112:1755\u201360.","journal-title":"Proc Natl Acad Sci USA"},{"key":"2076_CR33","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.mito.2012.06.003","volume":"13","author":"C Cerella","year":"2013","unstructured":"Cerella C, Dicato M, Diederich M. Assembling the puzzle of anti-cancer mechanisms triggered by cardiac glycosides. Mitochondrion. 2013;13:225\u201334.","journal-title":"Mitochondrion"},{"key":"2076_CR34","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/nchembio.476","volume":"7","author":"J Ye","year":"2011","unstructured":"Ye J, Chen S, Maniatis T. Cardiac glycosides are potent inhibitors of interferon-beta gene expression. Nat Chem Biol. 2011;7:25\u201333.","journal-title":"Nat Chem Biol"},{"key":"2076_CR35","doi-asserted-by":"crossref","first-page":"e8292","DOI":"10.1371\/journal.pone.0008292","volume":"4","author":"A Perne","year":"2009","unstructured":"Perne A, Muellner MK, Steinrueck M, Craig-Mueller N, Mayerhofer J, Schwarzinger I, et al. Cardiac glycosides induce cell death in human cells by inhibiting general protein synthesis. PLoS One. 2009;4:e8292.","journal-title":"PLoS One"},{"key":"2076_CR36","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1177\/1087057112466698","volume":"18","author":"MC Didiot","year":"2013","unstructured":"Didiot MC, Hewett J, Varin T, Freuler F, Selinger D, Nick H, et al. Identification of cardiac glycoside molecules as inhibitors of c-Myc IRES-mediated translation. J Biomol Screen. 2013;18:407\u201319.","journal-title":"J Biomol Screen"},{"key":"2076_CR37","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.bcp.2013.12.002","volume":"89","author":"J Cao","year":"2014","unstructured":"Cao J, He L, Lin G, Hu C, Dong R, Zhang J, et al. Cap-dependent translation initiation factor, eIF4E, is the target for Ouabain-mediated inhibition of HIF-1alpha. Biochem Pharmacol. 2014;89:20\u201330.","journal-title":"Biochem Pharmacol"},{"key":"2076_CR38","doi-asserted-by":"crossref","first-page":"117147","DOI":"10.1016\/j.lfs.2019.117147","volume":"241","author":"D Reddy","year":"2020","unstructured":"Reddy D, Kumavath R, Tan TZ, Ampasala DR, Kumar AP. Peruvoside targets apoptosis and autophagy through MAPK Wnt\/beta-catenin and PI3K\/AKT\/mTOR signaling pathways in human cancers. Life Sci. 2020;241:117147.","journal-title":"Life Sci"},{"key":"2076_CR39","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1016\/j.cell.2017.10.049","volume":"171","author":"A Subramanian","year":"2017","unstructured":"Subramanian A, Narayan R, Corsello SM, Peck DD, Natoli TE, Lu X, et al. A next generation connectivity map: L1000 platform and the first 1,000,000 profiles. Cell. 2017;171:1437\u201352 e1417.","journal-title":"Cell"},{"key":"2076_CR40","first-page":"359ra129","volume":"8","author":"SS Lam","year":"2016","unstructured":"Lam SS, Ho ES, He BL, Wong WW, Cher CY, Ng NK, et al. Homoharringtonine (omacetaxine mepesuccinate) as an adjunct for FLT3-ITD acute myeloid leukemia. Sci Transl Med. 2016;8:359ra129.","journal-title":"Sci Transl Med"},{"key":"2076_CR41","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/j.tips.2020.09.004","volume":"41","author":"C Cerella","year":"2020","unstructured":"Cerella C, Dicato M, Diederich M. BH3 mimetics in AML therapy: death and beyond? Trends Pharmacol Sci. 2020;41:793\u2013814.","journal-title":"Trends Pharmacol Sci"},{"key":"2076_CR42","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1111\/bph.15423","volume":"179","author":"A Olona","year":"2022","unstructured":"Olona A, Hateley C, Guerrero A, Ko JH, Johnson MR, Anand PK, et al. Cardiac glycosides cause cytotoxicity in human macrophages and ameliorate white adipose tissue homeostasis. Br J Pharmacol. 2022;179:1874\u201386.","journal-title":"Br J Pharmacol"},{"key":"2076_CR43","doi-asserted-by":"crossref","first-page":"895","DOI":"10.3389\/fphys.2017.00895","volume":"8","author":"LHA Cavalcante-Silva","year":"2017","unstructured":"Cavalcante-Silva LHA, Lima EA, Carvalho DCM, de Sales-Neto JM, Alves AKA, et al. Much more than a cardiotonic steroid: modulation of inflammation by ouabain. Front Physiol. 2017;8:895.","journal-title":"Front Physiol"},{"key":"2076_CR44","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.ccr.2012.02.028","volume":"21","author":"G Wei","year":"2012","unstructured":"Wei G, Margolin AA, Haery L, Brown E, Cucolo L, Julian B, et al. Chemical genomics identifies small-molecule MCL1 repressors and BCL-xL as a predictor of MCL1 dependency. Cancer Cell. 2012;21:547\u201362.","journal-title":"Cancer Cell"},{"key":"2076_CR45","doi-asserted-by":"crossref","first-page":"70","DOI":"10.3389\/fphar.2018.00070","volume":"9","author":"NFZ Schneider","year":"2018","unstructured":"Schneider NFZ, Cerella C, Lee JY, Mazumder A, Kim KR, de Carvalho A, et al. Cardiac glycoside glucoevatromonoside induces cancer type-specific cell death. Front Pharmacol. 2018;9:70.","journal-title":"Front Pharmacol"},{"key":"2076_CR46","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1080\/00498254.2017.1381779","volume":"48","author":"MS Chiney","year":"2018","unstructured":"Chiney MS, Menon RM, Bueno OF, Tong B, Salem AH. Clinical evaluation of P-glycoprotein inhibition by venetoclax: a drug interaction study with digoxin. Xenobiotica. 2018;48:904\u201310.","journal-title":"Xenobiotica"},{"key":"2076_CR47","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1093\/toxsci\/kfs307","volume":"131","author":"E Gozalpour","year":"2013","unstructured":"Gozalpour E, Wittgen HG, van den Heuvel JJ, Greupink R, Russel FG, Koenderink JB. Interaction of digitalis-like compounds with p-glycoprotein. Toxicol Sci. 2013;131:502\u201311.","journal-title":"Toxicol Sci"},{"key":"2076_CR48","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1002\/cplu.201700151","volume":"82","author":"N Funt","year":"2017","unstructured":"Funt N, Palmer BA, Weiner S, Addadi L. Koi Fish-Scale iridophore cells orient guanine crystals to maximize light reflection. Chempluschem. 2017;82:914\u201323.","journal-title":"Chempluschem"},{"key":"2076_CR49","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.cell.2019.12.023","volume":"180","author":"DP Nusinow","year":"2020","unstructured":"Nusinow DP, Szpyt J, Ghandi M, Rose CM, McDonald ER 3rd, Kalocsay M, et al. Quantitative proteomics of the cancer cell line encyclopedia. Cell. 2020;180:387\u2013402 e316.","journal-title":"Cell"},{"key":"2076_CR50","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.3109\/10428194.2014.944523","volume":"56","author":"H Hackl","year":"2015","unstructured":"Hackl H, Steinleitner K, Lind K, Hofer S, Tosic N, Pavlovic S, et al. A gene expression profile associated with relapse of cytogenetically normal acute myeloid leukemia is enriched for leukemia stem cell genes. Leuk Lymphoma. 2015;56:1126\u20138.","journal-title":"Leuk Lymphoma"},{"key":"2076_CR51","doi-asserted-by":"crossref","first-page":"3839","DOI":"10.1038\/onc.2015.455","volume":"35","author":"F Radogna","year":"2016","unstructured":"Radogna F, Cerella C, Gaigneaux A, Christov C, Dicato M, Diederich M. Cell type-dependent ROS and mitophagy response leads to apoptosis or necroptosis in neuroblastoma. Oncogene. 2016;35:3839\u201353.","journal-title":"Oncogene"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41375-023-02076-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-023-02076-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-023-02076-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,9]],"date-time":"2024-01-09T09:04:24Z","timestamp":1704791064000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-023-02076-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,30]]},"references-count":51,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["2076"],"URL":"https:\/\/doi.org\/10.1038\/s41375-023-02076-8","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,30]]},"assertion":[{"value":"20 March 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 October 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 October 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 October 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}